Who Paid My Doc
Mylotarg
Biological Oncology
NDC 0008-4510-01
General payments
$274,992
Research payments
$18,459,600
Through program year 2025, $274,992 in general payments and $18,459,600 in research payments were reported against Mylotarg (Oncology).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
14 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $5,700 | 1 |
| 2025 | Research | $850,976 | 7 |
| 2024 | General | $20 | 1 |
| 2024 | Research | $1,315,212 | 12 |
| 2023 | General | $450 | 17 |
| 2023 | Research | $995,094 | 16 |
| 2022 | General | $34,865 | 34 |
| 2022 | Research | $3,081,350 | 17 |
| 2021 | General | $15,259 | 12 |
| 2021 | Research | $3,161,881 | 21 |
| 2020 | General | $3,665 | 16 |
| 2020 | Research | $4,557,671 | 62 |
| 2019 | General | $215,034 | 1,421 |
| 2019 | Research | $4,497,417 | 44 |
Breakdown
Each share is of general payments naming this product in 2025.
Each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
Each share is of general payments naming this product in 2025 where a state was reported.
Records
1,502 general · 179 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.